KDR and gastric cancer: After molecular targeted agents have been introduced for treatment of GC, trastuzumab which targets HER-2 (human epidermal receptor-2), and ramucirumab which targets VEGFR-2 (vascular endothelial growth factor receptor-2) proved their clinical efficacies in large clinical trials [7–9].